Clinical Trials Using Sapacitabine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sapacitabine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Olaparib and Sapacitabine in Treating Patients with Metastatic or Unresectable BRCA Mutant Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of sapacitabine when given together with olaparib and to see how well they work in treating patients with BRCA mutant breast cancer that has spread to other parts of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sapacitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and sapacitabine may work better in treating patients with metastatic or unresectable BRCA mutant breast cancer.
    Location: 2 locations

  • A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

    The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.
    Location: 2 locations

  • Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes

    This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
    Location: M D Anderson Cancer Center, Houston, Texas